Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.61 |
| ▸ | CTSS | P25774 | 10/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429918 | 1.00 | CTSK (0.61) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL1429799 | 1.00 | CTSK (0.61) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL7788744 | 0.87 | CTSK (0.55) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL7788178 | 0.87 | CTSK (0.55) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL28613325 | 0.86 | CTSS (0.48) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL28613327 | 0.86 | CTSS (0.48) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL8139777 | 0.84 | CTSK (0.58) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL17533115 | 0.83 | CTSS (0.46) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL4657580 | 0.83 | CTSK (0.57) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL29651451 | 0.83 | CTSS (0.64) | CTSKCTSSCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778162-A | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-112778162-B | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-112778162-A | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1006122-B1 | PHENETHYLAMINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-6255285-B1 | GASTROINTESTINAL DISORDERS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-1006122-A1 | PHENETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-06-07 | — | — | EP | disclosed |
| US-5856326-A | ANTITUMOR, ANTICANCER AGENTS | MERCK & CO., INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5780492-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | CTSK 553/4885CTSS 1285/4885CTSL 2045/4885 |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | CTSK 553/4885CTSS 1285/4885CTSL 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.